Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 06: Pipeline landscape PART 07: Market segmentation therapeutic area • Chemotherapy-induced anemia • Chemotherapy-induced neutropenia • Cancer pain • CINV • Others PART 08: Geographical segmentation • Cancer supportive care market in Americas • Cancer supportive care market in EMEA • Cancer supportive care market in APAC PART 09: Decision framework PART 10: Drivers and challenges • Market drivers • Market challenges PART 11: Market trends • Advent of biosimilars in cancer-associated treatment • Outsourcing of biosimilars manufacturing activities PART 12: Vendor landscape • Competitive scenario PART 13: Key vendor analysis • Amgen • Helsinn Healthcare • Johnson & Johnson • Merck • Other prominent vendors PART 14: Appendix • List of abbreviations   List of Exhibits Exhibit 01: Categories of cancers Exhibit 02: Various modes applied for treatment of cancer Exhibit 03: Side effects of various cancer treatments Exhibit 04: Major drug classes used as cancer supportive agents Exhibit 05: Global cancer supportive care market snapshot Exhibit 06: Global cancer supportive care market 2016-2021 ($ billions) Exhibit 07: Opportunity analysis in global cancer supportive care market Exhibit 08: Five forces analysis Exhibit 09: Key molecules in different stages of development Exhibit 10: Key clinical trials Exhibit 11: Segmentation of global cancer supportive care market by therapeutic area 2016 Exhibit 12: Segmentation of global cancer supportive care market by therapeutic area 2016 and 2021 Exhibit 13: Symptoms of anemia Exhibit 14: Types of anemia Exhibit 15: Global cancer supportive care market for chemotherapy-induced anemia 2016-2021 ($ billions) Exhibit 16: Types of cancers closely associated with anemia Exhibit 17: Commonly used ESAs Exhibit 18: Side effects associated with the usage of ESAs Exhibit 19: Global cancer supportive care market for chemotherapy-induced neutropenia 2016-2021 ($ billions) Exhibit 20: Types of cancer pain Exhibit 21: Global cancer supportive care market for cancer pain 2016-2021 ($ billions) Exhibit 22: Global cancer supportive care market for CINV 2016-2021 ($ billions) Exhibit 23: Major drug classes used for treatment of CINV Exhibit 24: Analysis of global CINV drugs market Exhibit 25: Global cancer supportive care market for others 2016-2021 ($ billions) Exhibit 26: Some of the other side effects of cancer treatment Exhibit 27: Effect of cancer treatment leading to oral complications Exhibit 28: Segmentation of global cancer supportive care market by geography 2016 and 2021 Exhibit 29: Segmentation of global cancer supportive care market by geography 2016-2021 ($ billions) Exhibit 30: Market scenario in Americas Exhibit 31: Cancer supportive care market in Americas 2016-2021 ($ billions) Exhibit 32: Top 10 types of cancers in US 2014 (per 100,000 people) Exhibit 33: Cancer survivors in US: Statistics and estimations 2016 and 2026 Exhibit 34: Economic and healthcare expenditure snapshot of US 2014 and 2015 ($ billions) Exhibit 35: Economic and healthcare snapshot of Canada 2016 Exhibit 36: New cases of cancer in Canada 2016 Exhibit 37: Market scenario in EMEA Exhibit 38: Cancer supportive care market in EMEA 2016-2021 ($ billions) Exhibit 39: Economic and healthcare snapshot of European region 2014 Exhibit 40: Cancer death statistics in EU 2015 Exhibit 41: Market scenario in APAC Exhibit 42: Cancer supportive care market in APAC 2016-2021 ($ billions) Exhibit 43: Cancer facts in China 2015 Exhibit 44: Cancer cases snapshot Exhibit 45: Estimated investment in oncology in developed and developing countries 2017 Exhibit 46: Common side effects associated with treatment of cancer in traditional methods Exhibit 47: General side effects of radiotherapy Exhibit 48: Support care drugs and their effects Exhibit 49: Demographic and economic snapshot of India and China 2014 and 2016 Exhibit 50: Factors contributing to high cost of cancer drugs Exhibit 51: Effect of high cost of cancer drugs on cancer supportive care market Exhibit 52: Top concerns of health insurance in US Exhibit 53: Competitive structure analysis of global cancer supportive care market 2016 Exhibit 54: Amgen: Key highlights Exhibit 55: Amgen: Strength assessment Exhibit 56: Amgen: Strategy assessment Exhibit 57: Amgen: Opportunity assessment Exhibit 58: Helsinn Healthcare: Key highlights Exhibit 59: Helsinn Healthcare: Strength assessment Exhibit 60: Helsinn Healthcare: Strategy assessment Exhibit 61: Helsinn Healthcare: Opportunity assessment Exhibit 62: Johnson & Johnson: Key highlights Exhibit 63: Johnson & Johnson: Strength assessment Exhibit 64: Johnson & Johnson: Strategy assessment Exhibit 65: Johnson & Johnson: Opportunity assessment Exhibit 66: Merck: Key highlights Exhibit 67: Merck: Strength assessment Exhibit 68: Merck: Strategy assessment Exhibit 69: Merck: Opportunity assessment

Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck, F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.